Intra-arterial liposomal @entity632 for metastatic XXXX .

@entity632 @entity1 @entity1665 @entity137 @entity390 @entity3136 @entity417 @entity96 @entity5 @entity882 @entity391 @entity1431 @entity694 @entity1370 @entity356
A liposome-entrapped liposome form of @entity632 (Lip-ADM) has been demonstrated to cause less myocardial and gastrointestinal @entity137 than free ADM. In the present study, Lip-ADM prepared by the remote loading method was administered to 3 @entity1 with metastatic @entity96 via a reservoir with the catheter located in the proper hepatic artery. The @entity5 was @entity356 in 2 @entity1 and sigmoid @entity694 in 1. Lip-ADM was administered at doses of 10, 20 or 50 mg per time. The total ADM dose was 170, 490, and 760 mg, respectively. No severe adverse effects, such as @entity390 , @entity391 , @entity3136 , @entity1665 or @entity1370 , were observed in any of the @entity1 . Although mild @entity1431 (2,800/microliters) was observed in 1 @entity1 , @entity417 or @entity882 did not occur. The survival time was respectively 6, 15, and 17 months from the start of Lip-ADM administration. A partial response was obtained in 1 @entity1 and stable disease in 1 @entity1 . Administration of Lip-ADM via a reservoir appears to be a useful treatment for @entity1 with metastatic @entity96 , since the low @entity137 of this preparation allows an increase of the total dose of ADM.
